objectives To explore the relationship between Efavirenz (EFV) and neuropsychiatric symptoms among adults and adolescents living with human immunodeficiency virus (HIV) in Kilimanjaro, Tanzania.
Introduction
Human Immunodeficiency Virus (HIV) is a major public health problem in Tanzania with an estimated prevalence of 5.3% and incidence of 0.26% in 2014 [1] . The number of people living with HIV (PLHIV) with access to combination antiretroviral treatment (cART) has increased steadily and close monitoring of cART use and its side effects is warranted. In line with WHO recommendations, the current standard first-line treatment regimen for PLHIV consists of tenofovir, lamivudine and efavirenz (EFV) [2, 3] . EFV is a highly effective antiretroviral agent that penetrates well into the central nervous system (CNS) [4] . This contributes to the suppression of HIV in the CNS [4] , but may also contribute to the development of neuropsychiatric adverse effects. These adverse effects vary from mild concentration or sleeping disturbances to more severe symptoms of depression, anxiety and psychosis [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] .
A number of reviews on studies and clinical trials conducted in resource-rich settings among adults have indicated that neuropsychiatric side effects of EFV are common with a prevalence of up to 79% of EFV-treated adults living with HIV [5, 7, 10, 12, 15, 18, 22] . Studies demonstrate that symptoms are transient in the majority of PLHIV [9, 10, 22] . Yet, in a longitudinal study by Guti errez et al. [8] , 59% of PLHIV still had symptoms after 6 months of treatment. The suggestion of long-term EFV neurotoxicity is also supported by several cross-sectional studies [14, 23, 24] . Importantly, treatment discontinuation in PLHIV with neuropsychiatric symptoms has been reported differently in several studies, but range from 18% to as high as 54% in different studies [5, 8, 11, 16, 23, 25, 26] . Therefore, EFV neurotoxicity not only affects quality of life (QoL), but also affects adherence to treatment, which may subsequently lead to resistance formation [27] .
Pharmacokinetic aspects of EFV may also play an important role in CNS toxicity, as the risk for CNS toxicity seems closely related to EFV plasma levels [8, 28] . EFV is metabolised by cytochrome CYP2B6, with carriers of the 516G>T allelic variant of the CYP2B6 genotype being poor EFV metabolisers [29] . These individuals are at increased risk to develop neuropsychiatric symptoms during EFV treatment [30, 31] . Importantly, this allelic variant has been shown to be more prevalent among Europeans and Americans of African descendence (about 50%), compared to Caucasian individuals (about 25%), meaning these individuals may be at an increased risk to develop neuropsychiatric symptoms during EFV treatment [29] . Data on EFV neurotoxicity from sub-Sahara Africa are however limited, despite the common use of EFV.
There is a similar lack of data on neuropsychiatric adverse events of EFV among children and adolescents living with HIV [32] . Only one small-scale cross-sectional study from the African continent, among children living with HIV in Uganda, suggested that the risk of having CNS symptoms did not differ between children on EFV and children on nevirapine [33] . Given the potential neurotoxic effects of EFV, with possible consequences for the developing brains of children and adolescents, and the potential interference of psychiatric symptoms during this critical window of psychosocial development, additional data on neuropsychiatric adverse effects of EFV in children and adolescents are urgently needed [32] .
In the present cross-sectional study, neuropsychiatric symptoms were evaluated in adult and adolescent Tanzanian individuals living with HIV, comparing those with an EFV or a non-EFV-based cART regimen. We hypothesised that EFV treatment is associated with higher psychiatric symptom levels and poorer QoL, compared to non-EFV ART.
Methods

Study design and ethics
We performed a cross-sectional study, comparing PLHIV taking an EFV and a non-EFV-based cART regimen. The study was approved by the institutional review board of Kilimanjaro Christian University Medical College (KCMUCo) and the National Institute of Medical Research (NIMR) of Tanzania (protocol nr NIMR/HQ/ R.8a/Vol. IX/2229).
Study population
ARV-treated adults and adolescents were recruited from March till September 2015 at the Child Centred Family Care Centre (CCFCC) of Kilimanjaro Christian Medical Centre (KCMC) in Moshi, Tanzania. KCMC follows the National Guidelines for Management of HIV [2] . At the time that participants of our study started ARV (before 2015), the default first-line regimen included either EFV or nevirapine (NVP). In fact, EFV was the main choice, but several reasons such as child-bearing age, pregnancy, non-availability of EFV and other indefinable reasons made PLHIV to start with NVP instead of EFV. Inclusion criteria were documented HIV infection, at least 6 months use of cART and age 12 years or older. Six months stable ARV was used as a criterium as we only wanted to include participants who are settled with their treatment. In this research, we wanted to look at possible lasting neuropsychiatric side effects of ARV medication. Most side effects at the beginning of starting a drug are transient. Although transient side effects are also relevant, the main focus of this research was on persisting neuropsychiatric side effects that may therefore impair QoL and adherence to treatment in the long-term exclusion criteria were pregnancy, severe conditions interfering with informed consent or participation (including e.g. psychosis, severe cognitive impairment). We wanted to show a difference of 10% in the proportion of patients having neuropsychiatric symptoms, with an a of 0.05 and power of 80% (b = 0.2). Therefore, we needed a total sample of 100 patients in each group. This means, we had to include 100 adolescents using EFV and 100 adolescents not using EFV. For adults, we needed the same numbers, 100 on EFV and 100 without EFV. Data collection took about six months.
Instruments
Using questionnaires and structured clinical interviews, data were collected on demographics, clinical characteristics (HIV treatment, testing history and missed pills in the past week/month) and neuropsychiatric symptom levels.
To investigate anxiety and depression, we used the Hospital Anxiety and Depression Scale (HADS) developed by Zigmond and Snaith [34] . It contains 14 statements on past week symptom levels. Answers are on a four-point Likert scale. Example questions are 'I get a sort of frightened feeling as if something awful is about to happen' and 'I look forward with enjoyment to things' It has two subscales: one for depression and one for anxiety. The HADS has excellent validity and is a reliable instrument to assess anxiety and depression in a variety of clinical populations in different countries [35] . It has not been validated in Kiswahili, but showed good reliability and validity in Ethiopia [36] .
The symptom checklist 90 (SCL-90) was used to assess a broad range of psychological problems and symptoms of psychopathology during the past week [37] . It has 90 questions. Answers are on a five-point Likert scale (0: not at all to 4: extremely). Example symptoms are 'feeling easily annoyed or irritated' and 'trouble falling asleep'. The SCL-90 has nine subscales: somatisation, obsessivecompulsive, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation and psychoticism. The SCL-90 demonstrates excellent psychometric properties in various populations in different countries [37] . It has been used in several studies in Africa, but there has been no research on psychometric properties in Africa.
The Mini-International Neuropsychiatric Interview (MINI) is a clinical interview, used to screen psychiatric disorders, according to DSM-IV and ICD-10 criteria [38] . It covers most common axis one disorders, including mood disorders, anxiety disorders, psychotic disorders, obsessive-compulsive disorder and substance use disorders. It is among the most commonly applied structured clinical interviews for the assessment of psychiatric disorders, particularly in research settings [38] . There is ample evidence for its reliability in various populations worldwide [38] . Several sections, mainly on alcohol and substance abuse, have been widely used in Africa, but only one study on validation was carried out in Morocco with excellent psychometric properties [39] .
We screened for problematic alcohol use using the alcohol use disorders identification test (AUDIT). This questionnaire was developed by the WHO and contains ten questions on alcohol use [40] . An overall score can be calculated, by summing all answers. The AUDIT is commonly applied worldwide to screen for problematic alcohol use, with excellent validity and reliability including in East Africa [41] .
Quality of life was assessed using the WHO-QOL BREF. This is an instrument specifically for the assessment of QoL in HIV-infected individuals [42] . It has 120 questions with five-point Likert scales. Examples items are as follows: 'Do you feel happy about your relationship with you family members?' and 'How difficult is it for you to handle any pain or discomfort?' It covers four domains: physical health, psychological health, social relationships and environment. It has been widely used in Africa and translated in several African languages, but not in Kiswahili. In Malawi, it had good psychometric properties [43] .
Only among adolescents, we used the Strengths and Difficulties Questionnaire (SDQ), to more specifically assess adolescent mental health [44] . It contains 25 items with a three-point Likert scale (0: 'Not true', to 2: 'Certainly true'). The SDQ has five subscales: emotional problems, conduct problems, hyperactivity, peer problems and prosocial. The SDQ has been widely used in a variety of child and adolescent populations, with good psychometric properties [45] . It has also been used in Tanzania and was available in Kiswahili language [46] .
Adherence to treatment was measured by directly asking whether the participant missed any doses in the past week and in the past month. This was asked for each ARV separately. A cut-off score of 100% was used to define adherence and non-adherence. This approach has been proven to be well-related to pharmacy refill counts and viral load outcomes in a previous study among Dutch African PLHIV [47, 48] .
Apart from the SDQ, all questionnaires were translated into Kiswahili according to WHO guidelines [49] . First, a bilingual panel of three people (two clinicians, one sociologist) translated all items. Then, a team of monolingual persons including lay people checked and corrected the translated version, followed by two translators who worked on back translating. During the group discussions, we also discussed if all items were culturally appropriate. The bilingual panel then judged the translated and back-translated questionnaires to come a final consensus version.
Study procedures
PLHIV were asked for participation after their regular consultation at CCFCC with a nurse counsellor and/or physician using convenience sampling. In line with ethical regulations, written informed consent was obtained from each participant 18 years or older or from a parent or guardian for those below 18 years old. After written informed consent, the participant was interviewed by a research nurse, using a structured questionnaire containing all standardised questionnaires. All nurses were trained in psychiatric assessment in a 1-week training programme, by a team of a Dutch psychiatrist (AS), Medical Doctor (AD) and Mental Health researcher (MS) with experience in cross-cultural psychiatric assessments in Tanzania. Training was carried out using role-plays and all interviewers practiced several times while being judged by the research team. The medical doctor and Mental Health researcher were available for questions during the interviews and corroborated assessments.
Data analyses
Data were analysed using SPSS. Differences in demographics and disease and treatment history between EFV and non-EFV users were investigated using chi-squared tests for categorical variables and univariate t-test for continuous variables. We did Multivariate Analysis Of Variance (MANOVA) to explore relationships between EFV use and neuropsychiatric symptoms with correction for age, sex and variables that differed between those on EFV and those without. Post hoc, we also analysed whether being adult or adolescent is an effect modifier by adding an interaction term with adolescent or adult to the MANOVA analyses.
Results
Study participants
We included 215 adults and 150 adolescents. EFV use was part of the treatment in 113 (52%) adults and in 56 (37%) adolescents. Demographic and clinical characteristics of the study population are displayed in Table 1 . Demographic data were not different between EFV users and non-EFV users, both for adults and adolescents. Among adults and adolescents, the duration of confirmed HIV infection was shorter for EFV users (7.2 (SD 4.6) and 6.9 (SD 3.0) years, respectively) than for non-EFV users (8.0 (SD 4.1) and 9.0 (SD 3.4) years, respectively, with *Differences are tested using chi-squared tests. †Differences are tested using t-tests. ‡Mean (SD). P = 0.002 and P < 0.001). Also, EFV was part of the first cART for 65% of the adult patients while only 40% of the adult non-EFV group were treatment na€ ıve (P < 0.001). Adolescent EFV users more often had prior non-EFV regimens than those not on EFV (87% vs. 37%, P < 0.001).
Neuropsychiatric symptoms
Anxiety and depression. Nine adults reported clinical depression according to the HADS (8%). The HADS showed non-significant higher scores for adults on EFV (P = 0.06) after correction for age, sex, years since HIV positive and being treatment naive before starting the current regimen. Univariate analysis showed that this was mainly due to higher scores for depression (score: 4.5 (SD 3.9) vs. 3.4 (SD 3.2); P = 0.02). For adolescents, we found that HADS scores were significantly lower for those on EFV (P < 0.001) after correction for age, sex, years since HIV positive and being treatment naive before starting the current regimen. Univariate analyses showed that this was due to lower scores for depression (score 1.3 (SD 1.5) vs. 2.1 (SD 2.5); P < 0.001). Post hoc, we found that the relationship between EFV and depression is modified by being adolescent (P = 0.005) ( Table 2) .
Psychological symptoms (SCL-90). For adults, there was a trend in higher scores on psychological symptoms for those on EFV (P = 0.09), which was due to depression (0.8 (0.7) vs. 0.7 (0.7); P = 0.03), hostility (0.7 (0.7) vs. 0.6 (0.6); P = 0.04) and additional items (0.8 (0.6) vs. 0.7 (0.6); P = 0.05). For adolescents, we found lower scores on psychological symptoms for those on EFV (P = 0.03), which was due to lower scores on somatisation (0.3 (0.3) vs. 0.5 (0.4) P = 0.05), depression (0.2 (0.3) vs. 0.5 (0.5); P = 0.02) and additional items (0.2 (0.3) vs. 0.4 (0.5); P = 0.01). Post hoc, we found that the relationship between EFV and depression is being modified by being adolescent (P = 0.005) ( Table 2) .
Clinical Interview and SDQ. With the MINI questionnaire, we found six adults (3%) with a major current depressive episode, 21 adults (10%) with suicidal risk, two (1%) with hypomanic episode, three (1%) with agoraphobia without history of panic disorder, two (1%) with current social phobia, one with substance abuse (1%) which was marihuana and one (1%) with a current psychotic disorder. There were no differences between EFV users and non-EFV users. Among adolescents, we only found one psychotic disorder through the MINI. The SDQ showed no difference for adolescents (P = 0.6) after correction for age, sex, years since HIV positive and being treatment naive before starting the current regimen.
Alcohol abuse. Adults on EFV more often abused alcohol (11%) than those without EFV (1%; P = 0.003). There was no relationship between alcohol abuse and depression in univariate analyse (P > 0.1). Among adolescents, there were no alcohol abusers defined by the scores and there was no difference in alcohol abuse scores (P = 0.2).
Quality of life and treatment adherence. Among adults, there was no difference in QoL for those on EFV and those without EFV on the overall scale (P = 0.5) after correction for age, sex, years since HIV positive and being treatment naive before starting the current regimen. Univariate, social relations were not significantly lower for adults on EFV (P = 0.06). For adolescents, there was a trend of better scores in QoL for those on EFV (P = 0.1), mainly determined by better scores on physical QoL (17.7 (1.6) vs. 16.8 (2.0); P = 0.008), level of independence (14.8 (1.8) vs. 14.5 (2.3); P = 0.01) and environmental QoL (14.3 (1.9) vs. (13.5 (1.8) P = 0.008). There was no difference in 100% treatment adherence in the past week between adults on EFV and adults without EFV (P = 0.2) and for adolescents (P = 0.8). Post hoc, we found that the relationship of EFV with social relations and environmental QoL was modified by adolescent (P = 0.02) ( Table 2) .
Discussion
This study from Tanzania shows that the relationship between EFV and neuropsychiatric symptoms might differ between adults and adolescents. In line with the existing literature, adult EFV users scored higher on all of the used depression scales than adult non-EFV users [5, 8-10, 16, 21, 24, 50] . In contrast, adolescents on EFV showed lower levels of depressive symptoms on all scales than those without EFV. Post hoc analyses confirmed that age group (adolescents vs. adults) modified the relationship between EFV and depressive symptoms levels. Similarly, adults using EFV reported lower QoL on the social relationships domain compared to adult non-EFV users, while adolescents using EFV reported better QoL on social relationships, and the physical, level of independence, and environment domain. Furthermore, significantly more problematic alcohol use was found among adults on EFV compared to non-EFV regimens. But this was not related to depressive symptoms. Ten per cent of adult participants reported suicidality, but there was no difference between EFV and non-EFV. To our knowledge, this is the first study to specifically look at neuropsychiatric events in adolescents and adults on EFV in sub-Saharan Africa. In contrast to adults, we found that adolescent EFV users experience fewer psychiatric symptoms than adolescents on non-EFV regimens.
One study in Uganda found that there was no difference in neuropsychiatric symptom levels between EFV and NVP users among children [33] . Yet, several issues might explain our observations. First, side effects of EFV may not be as prevalent in adolescents as in adults, due to lower vulnerability compared to adults. It has been suggested that serotonergic pathways play an important role in EFV's neuropsychiatric adverse effects. EFV affects serotonin signalling by interfering with the 5-HT2A receptor [32] . It is well-known that the effects of serotonergic agents differ between adults and adolescents and may even show opposite effects, as reviewed by Cousins and Goodyer [51] . The differential sensitivity to the neuropsychiatric side effects of EFV among adolescents and adults observed here may therefore be explained by differences in the stage of brain maturation, specifically within the serotonergic pathways. More research is needed to understand why adults and adolescents react differently to EFV. An alternative explanation for our findings might be that those not on EFV may have used EFV before and switched to another regimen because of psychiatric adverse effects. A large part of adults (40%) was on a non-EFV regimen as their first regimen. Selection bias in the EFV group of those resilient to psychiatric symptoms cannot be completely ruled out in a cross-sectional design. However, its several other factors favoured a non-EFV cART regimen in our sample, including previous guidelines having NVP as first-line treatment, preference of NVP in pregnant women as EFV is considered teratogenic, local availability of any of the NNRTIs, and personal preference of the prescribing health professional [2] . Apart from higher depression rates, also more problematic alcohol use was present in the adults taking EFV. There was no clear relationship between problematic alcohol use and depressive symptoms. It is therefore unlikely that depressive symptoms were caused by increased alcohol intake among adult EFV users or vice versa. It could be speculated that EFV might contribute to increased levels of alcohol use by other mechanisms, for example decreasing impulse control. As for depressive symptoms, the serotonergic, LSD-like properties of EFV may predispose some individuals for alcohol abuse [50] . It is tempting to speculate that, depending on individual differences within the serotonin pathway, EFV may increase levels of depression in some and levels of alcohol use in others.
In contrast to the observed effects on dimensional measures of depressive symptoms, we did not find any effect on dichotomous measures of psychopathology, using the MINI questionnaire. This discrepancy in our findings might on the one hand indicate low level of severity of depressive symptoms, below the threshold of clinical psychopathology, as observed in previous studies [7, 10, 13] . On the other hand, the MINI neuropsychiatric interview might not be appropriate for the assessment of psychopathology in the current context. For instance, the direct way of asking for psychiatric symptoms is not usual in Tanzania. Several other studies also found relationships of EFV with anxiety and mood disorders [10, 14, 24] , which we did not find. This could be due to the use of different assessment tools. For example, the questionnaires used here may be sensitive enough to detect all neuropsychiatric symptoms in our setting, despite good psychometric properties in different populations across the world. Moreover, stigmatisation and nondisclosure of neuropsychiatric symptoms in the Tanzanian context might also play a role. It may also be that Tanzanian HIV-infected patients are indeed more resilient to the neuropsychiatric side effects of EFV as observed in Western populations. Finally, as our participants were on cART for at least six months and neuropsychiatric side effects of EFV might subside over time [5, 9, 22, 23] , it may be that neuropsychiatric symptoms already subsided before our assessment.
A remarkable finding was the relatively high prevalence of suicidal thoughts irrespective of EFV use among adults (10%). This finding even exceeds the 1% suicidality prevalence among EFV users, as suggested in a review by Ford et al. [6] . Kenedi and Goford [10] also found increased suicide risks in EFV users in their review, a finding that was not confirmed in the present study. As data on suicidality among Tanzanian HIV-infected individuals are lacking, it is unclear how these findings should be interpreted.
The current study is limited by its cross-sectional design, so no causal inferences concerning the relationship between EFV and neuropsychiatric symptom levels can be made. Future longitudinal studies may lead to more conclusive results on causality. Another limitation is that the used questionnaires may not be sensitive enough to detect neuropsychological symptoms. Specifically in a mostly traditional Tanzanian population, where mental symptoms may be attributed to spiritual forces and witchcraft [52] , 'Western' conceptualisation of the symptoms may not be appropriate or recognised. In addition, not all instruments applied here were validated for Tanzanian adult populations, nor for adolescent populations. This may obscure our findings and is an important limitation when interpreting the results. At the time of study, no well-validated psychiatric assessment tools were available for the Tanzanian context. We selected a set of internationally accepted instruments, applied across different cultural contexts worldwide. Yet, confounding effects, for example lack of sensitivity, cannot be ruled out here. Future studies in large-scale Tanzanian populations are needed to further test psychometric properties of the instruments applied here for the Tanzanian context. Another limitation is the exclusion of PLHIV who recently started cART and participants with severe cognitive impairment. However, we purposely included only patients without severe cognitive impairment and on stable cART. First, severe cognitive impairment interferes with reliable assessment of neuropsychiatric symptoms and informed consent. Second, recently started cART often goes along with a recent HIV diagnosis. To avoid confounding effects of recent HIV diagnosis on psychological symptoms, we included only those with stable cART. Lastly, we did not measure any drug levels or presence of CYP2B6. We therefore cannot conclude whether psychiatric side effects of EFV in adults and lower levels of psychiatric symptoms among adolescent EFV users are related to EFV levels in blood or plasma.
In summary, our findings show an association between EFV and depression and problematic alcohol use among adult PLHIV. In adolescents, EFV does not seem to play a role in neuropsychiatric symptoms. Our results, in combination with the previous studies, argue for close monitoring of HIV positive adults in Sub-Sahara Africa on depression and alcohol use. Because of the burden of mental health conditions and alcohol abuse action should be taken as soon as depression is noted. This means referral to needed psychiatric care and/or switch of cART regimen. In addition, methods of measuring neuropsychiatric symptoms outside the Western industrialised world should be developed and investigated. Qualitative studies may be needed to explore conceptualisation of neuropsychiatric symptoms in the Tanzanians setting. As we found a high percentage of suicidality among our participants, more research is needed to further investigate suicidal ideations among Tanzanian PLHIV.
